ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings


RSS Latest in Cardiology from ACC.org

  • POTCAST: Arrhythmia Prevention Using Targeted Plasma Potassium Levels in ICD Patients
    A treatment-induced increase in plasma potassium levels reduced the risk of ventricular arrhythmias, in patients with ICDs and baseline plasma potassium levels of 4.3 mmol per liter or lower, based on findings from the POTCAST Trial presented at ESC Congress 2025 and simultaneously published in NEJM. This targeting of high-normal potassium levels also reduced unplanned […]
  • AMALFI: Remote Screening Using ECG Patch Demonstrated Modest Benefits in AFib Diagnosis
    Use of an ECG patch to remotely screen older patients at moderate-to-high stroke risk demonstrated modest benefits in long-term atrial fibrillation (AFib) diagnosis and anticoagulation exposure, based on findings from the AMALFI Trial presented at ESC Congress 2025 and simultaneously published in JAMA.
  • Low-Dose Colchicine May Slow Growth of Clonal Hematopoiesis
    Taking low-dose colchicine daily may slow the progression of clonal hematopoiesis (CH), based on a subanalysis of the LoDoCo2 trial presented at ESC Congress 2025 and simultaneously published in JACC.
  • DIGIT-HF: Digitoxin in Patients With HFrEF
    Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to findings from the DIGIT-HF trial presented at ESC Congress 2025 and simultaneously published in NEJM.
  • DOUBLE-CHOICE: Comparison of Anesthesia Strategies and Self-Expanding Valve Types For TAVI
    A minimalist approach to transcatheter aortic valve implantation (TAVI) using local anesthesia without sedation, was noninferior to the standard approach for the composite primary outcome of cardiovascular events and complications at 30 days, according to results from the DOUBLE-CHOICE Trial presented at ESC Congress 2025.